MedTrace Logo

Safety and Efficacy of Autologous SVF Cells in Treating Patients With Osteoarthritis

NCT02846675 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-09-11

No results posted yet for this study

Summary

it's a self-control, double blind study of autologous adipose-derived stromal vascular fraction (SVF) to treat 50 osteoarthritic knees of grade II or III (K-L scale) under IRB-approved protocol in a feasibility and safety study.

Conditions

Interventions

BIOLOGICAL

autologous SVF

SVF will be obtained from lipoaspirates of subjects which will contain more than 5 millions nucleated cells.

BIOLOGICAL

Placebo

a Placebo treatment without SVF cells

Sponsors & Collaborators

  • Shanghai East Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-01
Primary Completion
2017-07-31
Completion
2018-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02846675 on ClinicalTrials.gov